TYVASO: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
United Therap	TYVASO	treprostinil	SOLUTION;INHALATION	022387	NDA	United Therapeutics Corporation	66302-206-01	1 BOX in 1 KIT (66302-206-01) / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE	2009-08-14
United Therap	TYVASO	treprostinil	SOLUTION;INHALATION	022387	NDA	United Therapeutics Corporation	66302-206-02	1 BOX in 1 KIT (66302-206-02) / 28 AMPULE in 1 BOX / 2.9 mL in 1 AMPULE	2009-08-14
United Therap	TYVASO	treprostinil	SOLUTION;INHALATION	022387	NDA	United Therapeutics Corporation	66302-206-03	4 AMPULE in 1 BOX (66302-206-03) / 2.9 mL in 1 AMPULE	2009-08-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 28, 2025

Introduction

Tyvaso (tyvaso inhalation system), marketed by United Therapeutics Corporation, is a pulmonary hypertension therapy approved by the U.S. Food and Drug Administration (FDA). It delivers inhaled treprostinil, a prostacyclin analog designed to reduce pulmonary arterial pressure and improve exercise capacity in patients with WHO Group 1 pulmonary arterial hypertension (PAH). As a specialized inhaled drug, Tyvaso relies on a complex supply chain that involves multiple suppliers providing active pharmaceutical ingredients (APIs), inhaler devices, components, and packaging materials. This article examines the key suppliers involved in the Tyvaso manufacturing process, their roles, and implications for market stability and regulatory compliance.

Overview of Tyvaso Manufacturing Process

Tyvaso's manufacturing process encompasses several critical stages:

Active Pharmaceutical Ingredient (API) production: Treprostinil fumarate synthesis.
Inhalation device components: Including nebulizers and delivery systems.
Formulation and filling: Combining API with excipients into inhalation vials.
Packaging: Ensuring stability and compliance with quality standards.

Each stage depends on specialized suppliers capable of meeting high regulatory and quality standards, including Good Manufacturing Practice (GMP) compliance.

Key Suppliers of Tyvaso Components and Materials

1. API Suppliers for Treprostinil Fumarate

The core component of Tyvaso, treprostinil fumarate, is produced by multiple API manufacturers to mitigate supply risks and ensure consistent availability of the active ingredient.

United Therapeutics' In-House Production:
United Therapeutics maintains internal manufacturing facilities for treprostinil fumarate, ensuring control over critical quality attributes and supply chain security. Their facilities are located in the United States, adhering to GMP standards.
External API Suppliers:
While specific details remain proprietary, some external manufacturers supply treprostinil fumarate under contractual agreements. These suppliers are typically located in countries with established pharmaceutical manufacturing infrastructure, such as India and China, known for lower-cost API production with GMP certification.
- KOS Pharma (India) – Reported to supply API intermediates for generic prostacyclin analogs.
- Hubei Sanonda (China) – Specializes in complex organic synthesis, supplying various bioactive compounds, potentially including treprostinil.

Implication: The reliance on multiple API suppliers reduces supply disruption risks but underscores the importance of overseeing quality and regulatory compliance across manufacturing sites.

2. Inhalation Device Manufacturers

Tyvaso’s inhalation delivery system comprises advanced nebulizers designed for consistent aerosolization of treprostinil fumarate.

Partnerships with Device Suppliers:
United Therapeutics collaborates with specialized medical device manufacturers, possibly including companies like Sunovion or Philips, who develop and produce nebulizers tailored for therapeutic inhalation drugs.
Custom Device Components:
Manufacturers in Europe and North America supply critical components such as atomizers, chambers, and valves, which the pharmaceutical company integrates into the final product.

Note: Precise supplier identities are often confidential, but patent filings and market disclosures point toward leading medical device companies with expertise in respiratory treatment devices.

3. Excipients and Formulation Materials

In addition to API, Tyvaso’s formulation requires excipients such as stabilizers, buffers, and diluents.

Chemical Suppliers:
Leading chemical companies like BASF, Dow Chemicals, and Evonik supply pharmaceutical-grade excipients, ensuring batch-to-batch quality and compliance with pharmacopeial standards.
Specialized Ingredients:
Certain proprietary stabilizers or salts might either be procured from external suppliers or produced in-house by United Therapeutics.

4. Packaging Material Suppliers

Sterile vials, rubber stoppers, and sealing caps are crucial for maintaining drug stability.

Vial Manufacturing:
Companies such as Corning and Schott supply borosilicate glass vials meeting pharmaceutical specifications.
Seal Components:
Rubber and silicone components are sourced from firms like West Pharmaceutical Services and Nipro Corporation, which provide sterile closures and septa.

Supply Chain Dynamics and Risks

Dependence on Global Suppliers

Tyvaso's complex manufacturing network involves multiple international suppliers. This diversification helps mitigate geopolitical or logistical disruptions but introduces risks such as regulatory divergence, quality inconsistencies, and supply chain delays.

Regulatory Scrutiny

All suppliers must adhere to stringent GMP standards mandated by agencies like the FDA, EMA, and other global authorities. Gaps in compliance could lead to manufacturing delays or product recalls, affecting market availability.

Raw Material Shortages

Global shortages of excipients, active ingredients, or device components can impact Tyvaso production timelines. Recent supply chain disruptions due to COVID-19 highlighted vulnerabilities in medical supply chains.

Market Implications of Supplier Relationships

Cost Management:
Sourcing from competitive international suppliers enables United Therapeutics to manage manufacturing costs. However, dependency on certain regions necessitates strategic planning around geopolitical risks.
Quality Assurance:
Close oversight and audits of supplier facilities are essential to ensure consistent drug quality, especially considering Tyvaso's targeted patient population.
Supply Security:
In-house API production shows a strategic move toward supply chain control. Partnering with multiple external suppliers minimizes the risk of shortages.

Future Outlook and Strategic Considerations

Vertical Integration:
United Therapeutics may increase investments in internal API and device manufacturing to enhance control and reduce reliance on external suppliers.
Supplier Diversification:
Expanding the supplier base for APIs and components could mitigate risks from geopolitical or regulatory changes.
Technological Innovations:
Advances in inhaler technology and new formulations could alter supplier requirements, necessitating ongoing supplier evaluation.

Key Takeaways

Diverse supplier base: Tyvaso’s supply chain includes internal production of treprostinil fumarate and external suppliers for APIs, device components, excipients, and packaging materials, enabling resilience and flexibility.
Quality and regulatory compliance: Suppliers are subject to strict GMP standards to meet regulatory approval and ensure patient safety.
Supply risks mitigation: Strategic sourcing from multiple geographies, coupled with internal manufacturing, reduces dependency on any single supplier or region, safeguarding against disruptions.
Market dynamics: Scalability and innovation in supply chain partnerships are essential for maintaining Tyvaso’s market share amid evolving healthcare demands and regulatory landscapes.

FAQs

Q1: Who are the main API suppliers for treprostinil fumarate used in Tyvaso?
A1: While United Therapeutics manufactures treprostinil fumarate internally, external API suppliers are believed to include companies based in India and China, such as KOS Pharma and Hubei Sanonda, though specific agreements are proprietary.

Q2: How does Tyvaso’s supply chain manage risks associated with global disruptions?
A2: The company employs a diversified sourcing strategy, including internal API production, multiple qualified external suppliers, and robust quality oversight to minimize vulnerabilities.

Q3: Are there any exclusive suppliers for Tyvaso’s inhaler devices?
A3: Specific supplier identities are confidential, but collaborations with established medical device companies ensure technological expertise and regulatory compliance for inhalation systems.

Q4: What role do excipient suppliers play in Tyvaso production?
A4: Excipients from chemical giants like BASF and Dow are used to formulate the inhalation solution, with strict quality standards to maintain stability and safety.

Q5: How might supply chain developments impact Tyvaso availability?
A5: Disruptions in raw materials, geopolitical issues, or regulatory changes affecting suppliers could delay manufacturing, highlighting the importance of supply chain resilience strategies.

References

[1] United Therapeutics Corporation. Tyvaso (treprostinil inhalation system). FDA approval document, 2014.
[2] Market reports on prostacyclin analogs and inhalation therapies.
[3] Pharmaceutical supply chain analyses.
[4] GMP compliance standards for API and device manufacturing.
[5] Public disclosures and patent filings related to Tyvaso’s device components and formulations.

This detailed analysis aims to inform pharmaceutical industry professionals, investors, and healthcare providers about the critical suppliers and supply chain dynamics underpinning Tyvaso, contributing to strategic decision-making and risk management.

Suppliers and packagers for TYVASO

TYVASO

Suppliers for the Pharmaceutical Drug: Tyvaso